[State of the adrenoreceptor system and drug therapy].
Ugriumova
M O
MO
D000318:Adrenergic beta-Agonists / Q000009:adverse effects*; D000818:Animals; D001249:Asthma / Q000188:drug therapy; D004280:Dobutamine / Q000009:adverse effects; D004983:Ethanolamines / Q000009:adverse effects; D006801:Humans; D051379:Mice; D011433:Propranolol / Q000009:adverse effects; D051381:Rats; D011941:Receptors, Adrenergic / Q000502:physiology*; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D011943:Receptors, Adrenergic, beta / Q000502:physiology; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D013618:Tachyphylaxis
D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D011941:Receptors, Adrenergic; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D004280:Dobutamine; D011433:Propranolol; C009118:pirbuterol
Sostoianie adrenoretseptornogo apparata i medikamentoznaia terapiia.